PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Gane, Edward J.
TI  - Rapid Sustained HCV Viral Load Reductions Achieved with ACH-3102 Plus SOF
DP  - 2014  01
TA  - MD Conference Express
PG  - 9--10
VI  - 14
IP  - 48
4099  - http://mdc.sagepub.com/content/14/48/9.short
4100  - http://mdc.sagepub.com/content/14/48/9.full
AB  - ACH-3102 is a second-generation hepatitis C virus (HCV) nonstructural 5A (NS5A) protein inhibitor with potent activity against HCV genotype (GT)-1 through GT-6. An ongoing phase 2 open-label study evaluated the safety and efficacy of 8 and 6 weeks of ACH-3102 plus sofosbuvir therapy in treatment-naïve patients with chronic HCV GT-1 infection, as discussed in this article.